Terminated PHASE2 INTERVENTIONAL 3-arm NCT01336959

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

A Two-part, Randomized, Double-blind, Placebo-controlled, Single Dose Study of BCT197 for the Prevention of Acute Kidney Injury (AKI) in Patients Undergoing Elective Cardiac Surgery With Cardiopulmonary Bypass (CPB)

Sponsor: Mereo BioPharma

Conditions Acute Kidney Injury

Interventions BCT197 Part A BCT197 Part B Placebo

Updated 12 times since 2017 Last updated: Nov 4, 2020 Started: Sep 30, 2011 Primary completion: Nov 30, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Mereo BioPharma

See all terminations from Mereo BioPharma

Other Acute Kidney Injury trials with similar outcome

Browse all Acute Kidney Injury trials

This PHASE2 trial investigates Acute Kidney Injury and is currently terminated or withdrawn. Mereo BioPharma leads this study, which shows 12 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2

▶ Show 7 earlier versions

Dec 2021 — Dec 2022 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Dec 2020 — Jan 2021 [monthly]

Terminated PHASE2
Dec 2018 — Dec 2020 [monthly]

Terminated PHASE2
Jun 2018 — Dec 2018 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mereo BioPharma
Novartis

Data source: Mereo BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beersheba, Israel , Cleveland, United States , Falls Church, United States , Herzliya, Israel , Jerusalem, Israel , Lincoln, United States , Orange, United States , Petah Tikva, Israel , Rehovot, Israel , Saginaw, United States and 3 more locations